Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis-Reference-Cited by-同舟云学术

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis

Published:2016-02-15 Issue:19 Volume:7 Page:27044-27054
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Sheng Xinan¹,Chi Zhihong¹,Cui Chuanliang¹,Si Lu¹,Li Siming¹,Tang Bixia¹,Mao Lili¹,Lian Bin¹,Wang Xuan¹,Yan Xieqiao¹,Guo Jun¹

Affiliation:

1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer Medicine, Beijing, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis;Medicine;2023-09-08

2. Vascularized Composite Iliac Flap Grafting for Trapezial Metastasectomy in Clear Cell Renal Carcinoma;JBJS Case Connector;2023

3. Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study;Future Oncology;2022-04

4. Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer;Frontiers in Molecular Biosciences;2022-03-14

5. The role of sunitinib in the therapy of metastatic renal cell carcinoma;Meditsinskiy sovet = Medical Council;2020-07-30